Skip to content
Mavyret, Maviret(glecaprevir)
Maviret, Mavyret (glecaprevir) is a small molecule pharmaceutical. Glecaprevir was first approved as Maviret on 2017-07-26. It is used to treat hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Combinations
Mavyret
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Glecaprevir
+
Pibrentasvir
Tradename
Company
Number
Date
Products
MAVYRETAbbVieN-209394 RX2017-08-03
1 products, RLD, RS
MAVYRETAbbVieN-215110 RX2021-06-10
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
mavyretNew Drug Application2020-05-08
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hepatitis cD006526B19.2
Agency Specific
FDA
EMA
Expiration
Code
GLECAPREVIR / PIBRENTASVIR, MAVYRET, ABBVIE
2028-12-10PED
2028-06-10ODE-372
2026-10-30PED
2026-04-30ODE-232, ODE-233
2023-10-10PED
2023-04-10M-259
2023-03-26PED
2023-02-03PED
Patent Expiration
Patent
Expires
Flag
FDA Information
Glecaprevir / Pibrentasvir, Mavyret, Abbvie
112468662036-06-24DP
93218072035-06-05DP
RE489232035-05-08DP
102860292034-03-14U-3237, U-3238
114845342034-03-14U-3237
89371502032-05-18DS, DP
86480372032-01-19DS, DPU-2141, U-3237, U-3238
95869782030-11-06U-2141, U-3237, U-3238
100289372030-06-10U-2141, U-3237, U-3238
100397542030-06-10U-2141, U-3237, U-3238
ATC Codes
J: Antiinfectives for systemic use
J05: Antivirals for systemic use
J05A: Direct acting antivirals
J05AP: Antivirals for treatment of hcv infections
J05AP57: Glecaprevir and pibrentasvir
HCPCS
No data
Clinical
Clinical Trials
60 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis cD006526B19.2171611535
Chronic hepatitis cD019698EFO_0004220B18.24122117
Chronic kidney failureD007676EFO_0003884N18.62146
Renal insufficiencyD051437HP_0000083N19123
Chronic renal insufficiencyD051436N1822
Respiratory insufficiencyD012131HP_0002093J96.911
Kidney diseasesD007674EFO_0003086N0811
Heroin dependenceD006556EFO_000424011
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HepacivirusD0161744810
Hepatitis bD00650911315
Liver cirrhosisD008103EFO_0001422K74.01214
Post-traumatic stress disordersD013313EFO_0001358F43.1222
InfectionsD007239EFO_000054411
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B2011
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatic insufficiencyD04855011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Retinal diseasesD012164HP_0000479H35.911
Liver diseasesD008107EFO_0001421K70-K7711
Rna virus infectionsD01232711
Digestive system diseasesD004066EFO_0000405K92.911
HepatitisD006505HP_0012115K75.911
Viral hepatitis humanD006525EFO_000419611
Coronary artery diseaseD003324I25.111
MoralsD00901411
Opioid-related disordersD009293EFO_0005611F1111
HivD006678O98.711
Show 1 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGLECAPREVIR
INNglecaprevir
Description
Glecaprevir (INN,) is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that was identified jointly by AbbVie and Enanta Pharmaceuticals. It is being developed as a treatment of chronic hepatitis C infection in co-formulation with an HCV NS5A inhibitor pibrentasvir. Together they demonstrated potent antiviral activity against major HCV genotypes and high barriers to resistance in vitro.
Classification
Small molecule
Drug classantivirals: serine protease inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)(C)[C@@H]1NC(=O)O[C@@H]2CCC[C@H]2OC/C=C/C(F)(F)c2nc3ccccc3nc2O[C@@H]2C[C@@H](C(=O)N[C@]3(C(=O)NS(=O)(=O)C4(C)CC4)C[C@H]3C(F)F)N(C2)C1=O
Identifiers
PDB
CAS-ID1365970-03-1
RxCUI1940635
ChEMBL IDCHEMBL3545363
ChEBI ID
PubChem CID66828839
DrugBankDB13879
UNII IDK6BUU8J72P (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Mavyret - AbbVie
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,583 documents
View more details
Safety
Black-box Warning
Black-box warning for: Mavyret
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,981 adverse events reported
View more details